Mitchell E. Levinson bought $105k of PLSE
Chief Strategy Officer at Pulse Biosciences, Inc.. 17,800 shares at an average of $5.90, traded Nov 15, 2023, filed Nov 17, 2023.
Score components
- +15RoleOfficer
- +10Trade size$105k at market
- +6Relative to holdingsHoldings up 26%
- +4Price context27% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +60.8%, 3m +50.0%, 6m +27.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-23-032408, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2023 | POpen-market purchase Common Stock | +461 | $5.83 | $2,689 | 69,227 | Nov 17, 2023 |
| Nov 15, 2023 | POpen-market purchase Common Stock | +3,800 | $5.88 | $22k | 73,027 | Nov 17, 2023 |
| Nov 15, 2023 | POpen-market purchase Common Stockindirect: Spouse | +5,000 | $5.94 | $30k | 9,135 | Nov 17, 2023 |
| Nov 15, 2023 | POpen-market purchase Common Stockindirect: Immediate Family Member (1) | +200 | $5.92 | $1,184 | 934 | Nov 17, 2023 |
| Nov 15, 2023 | POpen-market purchase Common Stockindirect: Immediate Family Member (1) | +2,300 | $5.94 | $14k | 3,234 | Nov 17, 2023 |
| Nov 15, 2023 | POpen-market purchase Common Stockindirect: Immediate Family Member (2) | +100 | $5.94 | $594 | 834 | Nov 17, 2023 |
| Nov 15, 2023 | POpen-market purchase Common Stockindirect: Immediate Family Member (2) | +2,400 | $5.85 | $14k | 3,234 | Nov 17, 2023 |
| Nov 15, 2023 | POpen-market purchase Common Stockindirect: Immediate Family Member (3) | +100 | $5.90 | $590 | 834 | Nov 17, 2023 |
| Nov 15, 2023 | POpen-market purchase Common Stockindirect: Immediate Family Member (3) | +2,400 | $5.80 | $14k | 3,234 | Nov 17, 2023 |
| Nov 15, 2023 | POpen-market purchase Common Stockindirect: Immediate family member (4) | +1,039 | $6.13 | $6,372 | 1,039 | Nov 17, 2023 |
Related signals
Other insiders at Pulse Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | PLSEbuy Pulse Biosciences, Inc. | Liane Rae Teplitsky Chief Operating Officer | $100k 2,025 shares | +98% | |
| 38Weak | PLSEbuy Pulse Biosciences, Inc. | Liane Rae Teplitsky Chief Operating Officer | $100k 2,070 shares | - | |
| 47Moderate | Pulse Biosciences, Inc. | Robert W Duggan director, owner | $13M 660,233 shares | +1% | |
| 47Moderate | Pulse Biosciences, Inc. | Robert W Duggan director, owner | $13M 660,233 shares | +1% | |
| 59Moderate | Pulse Biosciences, Inc. | Paul A Laviolette Chief Executive Officer | $295k 15,000 shares | - | |
| 61Notable | Pulse Biosciences, Inc. | Paul A Laviolette Chief Executive Officer | $295k 15,000 shares | +1773% | |
| 0Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $118k 5,000 shares | -10% | |
| 25Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $1.4M 60,000 shares | -95% | |
| 25Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $1.4M 60,000 shares | -95% | |
| 0Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $85k 4,600 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.